ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för citarinostat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

18 träffar

Bibliografisk träff 2023-10-30

Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation.

Sinatra L, Vogelmann A, Friedrich F, Tararina MA, Neuwirt E, Colcerasa A, König P, Toy L, Yesiloglu TZ, Hilscher S, Gaitzsch L, Papenkordt N, Zhai S, Zhang L, Romier C, Einsle O, Sippl W, Schutkowski M, Gross O, Bendas G, Christianson DW, Hansen FK, Jung M, Schiedel M.

J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.3c01385

Bibliografisk träff 2023-09-25

Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma.

Liu L, Zhang L, Chen X, Yang K, Cui H, Qian R, Zhao S, Wang L, Su X, Zhao M, Wang M, Hu Z, Lu T, Zhu Y, Zhou QQ, Yao Y.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115833

Bibliografisk träff 2023-08-30

Tetrahydro-β-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity.

Chen X, Wang J, Zhao P, Dang B, Liang T, Steimbach RR, Miller AK, Liu J, Wang X, Zhang T, Luan X, Hu J, Gao J.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115776

Bibliografisk träff 2023-07-18

Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity.

Liu F, Liu C, Chai Q, Zhao C, Meng H, Xue X, Yao TP, Zhang Y.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c00977

Bibliografisk träff 2022-11-13

Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment.

Yang FF, Hu T, Liu JQ, Yu XQ, Ma LY.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114920

Bibliografisk träff 2022-02-04

Discovery of HDAC6-Selective Inhibitor NN-390 with <i>in Vitro</i> Efficacy in Group 3 Medulloblastoma.

Nawar N, Bukhari S, Adile AA, Suk Y, Manaswiyoungkul P, Toutah K, Olaoye OO, Raouf YS, Sedighi A, Garcha HK, Hassan MM, Gwynne W, Israelian J, Radu TB, Geletu M, Abdeldayem A, Gawel JM, Cabral AD, Venugopal C, de Araujo ED, Singh SK, Gunning PT.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c01585

Bibliografisk träff 2021-12-17

A review on the treatment of multiple myeloma with small molecular agents in the past five years.

Zhang Z, Liu X, Zhao L, Zhou Y, Shi J, Chen W, Li J.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.114053

Bibliografisk träff 2021-09-27

Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).

Li Y, Sang S, Ren W, Pei Y, Bian Y, Chen Y, Sun H.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.113874

Bibliografisk träff 2021-06-08

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.

Toutah K, Nawar N, Timonen S, Sorger H, Raouf YS, Bukhari S, von Jan J, Ianevski A, Gawel JM, Olaoye OO, Geletu M, Abdeldayem A, Israelian J, Radu TB, Sedighi A, Bhatti MN, Hassan MM, Manaswiyoungkul P, Shouksmith AE, Neubauer HA, de Araujo ED, Aittokallio T, Krämer OH, Moriggl R, Mustjoki S, Herling M, Gunning PT.

J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.1c00420

Bibliografisk träff 2021-02-12

Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.

Olaoye OO, Watson PR, Nawar N, Geletu M, Sedighi A, Bukhari S, Raouf YS, Manaswiyoungkul P, Erdogan F, Abdeldayem A, Cabral AD, Hassan MM, Toutah K, Shouksmith AE, Gawel JM, Israelian J, Radu TB, Kachhiyapatel N, de Araujo ED, Christianson DW, Gunning PT.

J Med Chem · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.0c01922

Bibliografisk träff 2021-02-01

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.

Zhang XH, Qin-Ma, Wu HP, Khamis MY, Li YH, Ma LY, Liu HM.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c01782

Bibliografisk träff 2020-09-29

Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.

Tavares MT, Kozikowski AP, Shen S.

Eur J Med Chem · research-article; review; journal article · DOI 10.1016/j.ejmech.2020.112887

Bibliografisk träff 2020-07-16

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.

Ho TCS, Chan AHY, Ganesan A.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.0c00830

Bibliografisk träff 2020-06-06

PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.

Gawel JM, Shouksmith AE, Raouf YS, Nawar N, Toutah K, Bukhari S, Manaswiyoungkul P, Olaoye OO, Israelian J, Radu TB, Cabral AD, Sina D, Sedighi A, de Araujo ED, Gunning PT.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2020.112411

Bibliografisk träff 2019-12-13

Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.

Shouksmith AE, Gawel JM, Nawar N, Sina D, Raouf YS, Bukhari S, He L, Johns AE, Manaswiyoungkul P, Olaoye OO, Cabral AD, Sedighi A, de Araujo ED, Gunning PT.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.9b00471

Bibliografisk träff 2019-09-24

N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.

Mehndiratta S, Lin MH, Wu YW, Chen CH, Wu TY, Chuang KH, Chao MW, Chen YY, Pan SL, Chen MC, Liou JP.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.111725

Bibliografisk träff 2019-09-04

Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.

Shen S, Hadley M, Ustinova K, Pavlicek J, Knox T, Noonepalle S, Tavares MT, Zimprich CA, Zhang G, Robers MB, Bařinka C, Kozikowski AP, Villagra A.

J Med Chem · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.9b00946

Bibliografisk träff 2018-07-31

Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.

Brindisi M, Senger J, Cavella C, Grillo A, Chemi G, Gemma S, Cucinella DM, Lamponi S, Sarno F, Iside C, Nebbioso A, Novellino E, Shaik TB, Romier C, Herp D, Jung M, Butini S, Campiani G, Altucci L, Brogi S.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2018.07.069